CME: From Stem Cells to ß-cells: Restoring Glycemic Control in Type 1 Diabetes Medical Education on ReachMD

Overview
This program is designed to increase knowledge of current disease management strategies for severe hypoglycemia and impaired awareness of hypoglycemia (IAH) and create awareness on the emerging stem cell-based treatments for patients with type 1 diabetes (T1D).
Target Audience
This activity has been designed to meet the educational needs of the interprofessional team, including endocrinologists, cardiologists, nephrologists, stem cell transplant surgeons, and other clinicians, involved in the management of patients with type 1 diabetes (T1D).
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Outline the burden of care and disease management strategies for severe hypoglycemia and impaired awareness of hypoglycemia in T1D patients
- Explain the mechanisms, current limitations, and successes of regenerative medicine therapy programs for use in T1D
- Interpret the safety and efficacy data of current transplantation therapies and how novel strategies can improve outcomes
Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and TotalCME, Inc. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Faculty Disclosure of Commercial Relationships
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all educational programs.

The following faculty have disclosed:

Melena D. Bellin, MD, faculty for this educational event, has received research funding from Viacyte and Dexcom; and received consulting fees from Insulet, Vertex, and Ariel Precision Medicine.

Thierry Berney, MD, MSc, faculty for this educational event, has no relevant financial relationships with ineligible companies.

Michael R. Rickels, MD, MS, faculty for this educational event, has received research funding from Dompe Farmaceutici S.p.A; and has received consulting fees from Sernova Corp., Vertex Pharmaceuticals, and Zealand Pharma.

Camilo Ricordi, chair for this educational event, has no relevant financial relationships with ineligible companies.
Planners and Managers Disclosure List
The following planners/reviewers/managers have disclosed:

William Mencia, MD, FACEHP, CHCP, reviewer for this educational event, has no relevant financial relationships with ineligible companies.

TotalCME, Inc. planners and managers have no relevant commercial relationships to disclose.

All the relevant financial relationships for these individuals have been mitigated.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and TotalCME, Inc. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of MedEd On The Go you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.
Acknowledgment
This activity is supported by an independent educational grant from Vertex Pharmaceuticals Incorporated.
Jointly provided by Global Learning Collaborative (GLC) and TotalCME, Inc.
Fee Statement
This activity is FREE to all participants.
Instructions for Completion
During the period 12/19/2022 through 12/19/2023, registered participants wishing to receive continuing education credit for this activity must follow these steps:
1. Read the learning objectives and faculty disclosures.
2. Answer a pre-program question.
3. View the program.
4. Complete the post-test with a score of 100%.
5. Complete activity evaluation.
6. Apply for credit and either bank your credits or print your certificate.
System Requirements
Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.
Publication Dates
Release Date: 12/19/2022
Expiration Date: 12/19/2023